Cardiac arrhythmias
Drug research and approvals for cardiac arrhythmias: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 738 studies of cardiac arrhythmias are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 738
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Prognostic Value of 2-Week ECG Monitoring After PCI in Acute Myocardial InfarctionNCT07947498 · Not applicable · Chungnam National University Hospital · starts Aug 2, 2024
- A Feasibility Study of a Wearable Arrhythmia Monitoring System (PulseON) in Stroke PatientsNCT07943065 · Not reported · University Hospitals Coventry and Warwickshire NHS Trust · starts Sep 16, 2026
- Comparison of Continuous Cardiac Rhythm Monitoring and Standard Care in Post-MI Patients With Significant Scar and…NCT07941349 · Not applicable · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · starts Apr 17, 2026
- CArdiac STereotactic Radiation Treatment for Ablation of ventRicular TachycardiaNCT07931014 · Not applicable · Cancer Research Antwerp · starts Feb 25, 2026
- AI-Based Tools for Stroke Diagnosis, Treatment and Outcome Prediction: a Multicentre Prospective Observational StudyNCT07924371 · Not reported · Hospital Universitari Vall d'Hebron Research Institute · starts Sep 28, 2026
- Multimodality Location Prediction Accuracy of Leadless Pacemaker PositioningNCT07908927 · Not applicable · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · starts May 13, 2026
- Structured Treatment and Resource Efficiency Assessment With Lean Six Sigma Integration for Pulmonary Vein IsolationNCT07910370 · Not applicable · St. Josefs-Hospital Wiesbaden GmbH · starts Oct 26, 2026
- A Comparison of Pulsed Field Ablation (PFA) vs Cryoablation for Atrial Fibrillation Under Deep SedationNCT07900685 · Not applicable · East Sussex Healthcare NHS Trust · starts Oct 19, 2026
- Renal Denervation in Patients With Atrial Fibrillation and HypertensionNCT07893821 · Not applicable · Pavel Antiperovitch · starts Aug 1, 2026
Approved 24 of 25
- PropafenoneBeta-1 adrenergic receptor antagonist
- QuinidineSodium channel alpha subunit blocker
- AmiodaroneHERG blocker
- DisopyramideSodium channel alpha subunit blocker
- FlecainideSodium channel protein type V alpha subunit blocker
- MoricizineSodium channel alpha subunit blocker
- ProcainamideSodium channel alpha subunit blocker
- PropranololBeta-1 adrenergic receptor antagonist
- SotalolBeta-1 adrenergic receptor antagonist
- VerapamilVoltage-gated L-type calcium channel blocker
- DofetilideHERG blocker
- IbutilideHERG blocker
- MexiletineSodium channel alpha subunit blocker
- TocainideSodium channel alpha subunit blocker
- AmilorideAmiloride-sensitive sodium channel, ENaC blocker
- LidocaineSodium channel alpha subunit blocker
- ZiprasidoneSerotonin 2a (5-HT2a) receptor antagonist
- EncainideSodium channel alpha subunit blocker
- Sparteine
- GlycopyrroniumMuscarinic acetylcholine receptor M3 antagonist
- AcebutololBeta-1 adrenergic receptor antagonist
- BretyliumNorepinephrine transporter substrate
- MilrinonePhosphodiesterase 3A inhibitor
- VernakalantKir3.1/Kir3.4 blocker
Phase 3 11
- Azimilide
- BacitracinC55-isoprenyl pyrophosphate inhibitor
- ColchicineTubulin inhibitor
- DiltiazemVoltage-gated L-type calcium channel blocker
- DigoxinSodium/potassium-transporting ATPase inhibitor
- CefazolinBacterial penicillin-binding protein inhibitor
- OlmesartanType-1 angiotensin II receptor antagonist
- Digitalis
- DronedaroneVoltage-gated L-type calcium channel blocker
- Ajmaline
- Hydroquinidine
Phase 2 12 of 16
- LandiololBeta-1 adrenergic receptor antagonist
- Rotigaptide
- MetoprololBeta-1 adrenergic receptor antagonist
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Celivarone
- AcetylcysteineGlutathione precursor
- BfpetDiagnostic
- Eleclazine
- Doconexent
- AZD-2927
- TedisamilVoltage-gated potassium channel blocker
- Cifenline
Phase 1 or earlier 5
- Danegaptide
- AcetaminophenCyclooxygenase inhibitor
- PhenylephrineAdrenergic receptor alpha-1 agonist
- DimethindeneHistamine H1 receptor antagonist
- OxytocinOxytocin receptor agonist
How its trials ended
764 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 102 whose ending is known, 34% met their primary endpoint, 5% missed it and 61% stopped early.
- Completed, result not reported32743%
- Ongoing21128%
- Status unknown12416%
- Stopped: other or unclear395%
- Met its primary endpoint355%
- Stopped: enrollment or feasibility142%
- Stopped: sponsor or business decision81%
- Missed its primary endpoint51%
- Stopped: lack of efficacy1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA